American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Marisa Wexler, MS, Senior Science Writer—
Articles by Marisa Wexler
COVID-19 complicates vascular problems in woman with Alagille
A 34-year-old woman with Alagille syndrome and vascular problems — who had been implanted with a stent for her narrowed pulmonary arteries — experienced…
First patient dosed in Phase 3 trial of hepatitis C combination therapy
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy bemnifosbuvir and ruzasvir in adults with chronic…
Liver tissue analysis may help ID, distinguish PFIC types: Study
Analyzing the presence of different proteins in liver tissue under a microscope can be used to help diagnose progressive familial intrahepatic cholestasis (PFIC) and…
MASLD tied to higher mortality risk from nearly every cause
Compared with the general population, the risk of death is nearly twice as high in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
Phase 1 trial of gene-editing therapy for hepatitis B cleared in US
Precision Biosciences has been given the go-ahead to expand a Phase 1 clinical trial testing PBGENE-HBV, its gene-editing therapy for chronic hepatitis…
New ABCB4 mutation found to be cause of PFIC3 in young woman
A new mutation in the ABCB4 gene was found to cause progressive familial intrahepatic cholestasis (PFIC) type 3 in a young woman, a case…
Cytokine levels may predict Kasai procedure outcome in biliary atresia
Blood levels of certain immune signaling molecules called cytokines may help to predict the likelihood of a successful outcome with the…
Bemnifosbuvir-ruzasvir Phase 3 trials in hepatitis C launch in April
Atea Pharmaceuticals plans to launch two parallel Phase 3 trials soon to test its investigational combination therapy of bemnifosbuvir and ruzasvir for people with…
Rezdiffra reduces scarring in MASH with compensated cirrhosis: Trial
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring for most people with compensated cirrhosis, or irreversible scarring in a still-functioning liver, due to metabolic…